Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Haemonetics Corp. (NYSE: HAE) closed at $75.38 up 0.40% from its previous closing price of $75.08. In other words, the price has increased by $0.40 from its previous closing price. On the day, 0.63 million shares were traded. HAE stock price reached its highest trading level at $76.4675 during the session, while it also had its lowest trading level at $74.63.
Ratios:
For a deeper understanding of Haemonetics Corp.’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 52.88. For the most recent quarter (mrq), Quick Ratio is recorded 2.33 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 1.35 whereas as Long-Term Debt/Eq ratio is at 1.35.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $90.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 26 ’24 when Strong Stewart W sold 4,312 shares for $91.15 per share. The transaction valued at 393,039 led to the insider holds 18,196 shares of the business.
Strong Stewart W bought 4,312 shares of HAE for $393,039 on Jul 26 ’24. On Jul 11 ’24, another insider, Lingamneni Anila, who serves as the EVP, Chief Technology Officer of the company, sold 2,136 shares for $90.00 each. As a result, the insider received 192,240 and left with 21,410 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 3857774848 and an Enterprise Value of 4808461824. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 33.77, and their Forward P/E ratio for the next fiscal year is 13.88. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.81. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.89 while its Price-to-Book (P/B) ratio in mrq is 4.26. Its current Enterprise Value per Revenue stands at 3.605 whereas that against EBITDA is 15.31.
Stock Price History:
Over the past 52 weeks, HAE has reached a high of $97.97, while it has fallen to a 52-week low of $70.74. The 50-Day Moving Average of the stock is -9.93%, while the 200-Day Moving Average is calculated to be -9.93%.
Shares Statistics:
For the past three months, HAE has traded an average of 586.51K shares per day and 485250 over the past ten days. A total of 50.79M shares are outstanding, with a floating share count of 50.57M. Insiders hold about 1.18% of the company’s shares, while institutions hold 119.08% stake in the company. Shares short for HAE as of 1723680000 were 5046161 with a Short Ratio of 8.60, compared to 1721001600 on 4674849. Therefore, it implies a Short% of Shares Outstanding of 5046161 and a Short% of Float of 15.42.
